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Abstract
Background: The Anaplastic Lymphoma Kinase (ALK) is an orphan receptor tyrosine kinase, which undergoes post-
translational N-linked glycosylation. The catalytic domain of ALK was originally identified in the t(2;5) translocation
that produces the unglycosylated oncogenic protein NPM-ALK, which occurs in Anaplastic Large Cell Lymphoma
(ALCL). Recently, both germline and somatic activating missense mutations of ALK have been identified in
neuroblastoma (NB), a pediatric cancer arising from neural crest cells. Moreover, we previously reported that ALK
expression is significantly upregulated in advanced/metastatic NB. We hypothesized that ALK function may depend
on N-linked glycosylation and that disruption of this post-translational modification would impair ALK activation,
regardless the presence of either gene mutations or overexpression.
Methods: We employed tunicamycin to inhibit N-linked glycosylation. The following ALK-positive NB cell lines
were used: SH-SY5Y and KELLY (ALK mutation F1174L), UKF-NB3 (ALK mutation R1275Q) and NB1 (ALK
amplification). As a control, we used the NB cell lines LA1-5S and NB5 (no ALK expression), and the ALCL cell line
SU-DHL1 (NPM-ALK).
Results: Tunicamycin treatment of ALK-positive NB cells resulted in a hypoglycosylated ALK band and in decreased
amounts of mature full size receptor. Concomitantly, we observed a marked reduction of mature ALK
phosphorylation. On the contrary, tunicamycin had no effects on NPM-ALK phosphorylation in SU-DHL1 cells.
Moreover, phosphorylation levels of ALK downstream effectors (AKT, ERK1/2, STAT3) were clearly impaired only in
ALK mutated/amplified NB cell lines, whereas no significant reduction was observed in both ALK-negative and
NPM-ALK-positive cell lines. Furthermore, inhibition of N-linked glycosylation considerably impaired cell viability
only of ALK mutated/amplified NB cells. Finally, the cleavage of the Poly-ADP-ribose-polymerase (PARP) suggested
that apoptotic pathways may be involved in cell death.
Conclusions: In this study we showed that inhibition of N-linked glycosylation affects ALK phosphorylation and
disrupts downstream pro-survival signaling, indicating that inhibition of this post-translational modification may be
a promising therapeutic approach. However, as tunicamycin is not a likely candidate for clinical use other
approaches to alter N-linked glycosylation need to be explored. Future studies will assess whether the efficacy in
inhibiting ALK activity might be enhanced by the combination of ALK specific small molecule and N-linked
glycosylation inhibitors.
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Background
Neuroblastoma (NB) is a pediatric cancer that arises
from neural crest cells committed to the adrenal
medulla and the sympathetic nervous system. NB
accounts for 7-10% of all childhood cancers and the dis-
ease prevalence is about one case in 7,000 live births
[1]. Most NB cases are sporadic and may occur either as
a localized disease with a favorable prognosis or as a
disseminated disease, which, on the contrary, has a
worse prognosis in children over 1 year of age and heav-
ily contributes to childhood cancer mortality [1]. In
2008, we participated in discovering that activating
germline missense mutations in the catalytic domain of
the Anaplastic Lymphoma Kinase (ALK) are a major
cause for predisposition to familial NB [2]. In addition,
ALK mutations were also found to be somatically
acquired in about 8% of sporadic NB cases, suggesting
that ALK is involved in NB carcinogenesis in at least a
subset of tumors [2-8]. Moreover, we have investigated
ALK expression levels in relationship with the presence
of ALK mutations and the clinical outcome of patients,
observing that ALK protein expression is significantly
upregulated in advanced/metastatic NB, regardless the
presence of gene mutations [7].
ALK is an orphan trans-membrane receptor tyrosine
kinase (RTK), which belongs to the insulin receptor
superfamily of RTKs. The catalytic domain of ALK was
originally identified in the t(2;5)(p23;q35) chromosomal
translocation that produces the unglycosylated onco-
genic fusion protein NPM-ALK, which occurs in Ana-
plastic Large Cell Lymphoma (ALCL) [9]. ALK is a
protein of approximately 180 kDa that consists of 1,620
amino acids and undergoes post-translational modifica-
tions such as glycosylation of asparagines, namely, N-
linked glycosylation. Indeed, ALK has 16 highly con-
served putative sites of N-linked glycosylation in the
extra-cellular portion. Consequently, the mature full-
length receptor has a molecular weight of about 220
kDa.
N-linked glycosylation is a highly regulated post-trans-
lational modification, which is involved in several biolo-
gical processes such as protein folding and
conformation, oligomerization, sorting, cell-cell interac-
tions, and targeting of proteins to sub- or extra-cellular
locations [10,11]. Moreover, several reports have shown
a crucial role of N-linked carbohydrates in cell-cycle
progression and cell viability [11]. This post-transla-
tional modification is initiated upon entry of the poly-
peptide into the lumen of the endoplasmic reticulum
and involves transfer of a carbohydrate moiety to an
asparagine (N) residue within a specific amino acid con-
sensus sequence (i.e. NXS/T). The carbohydrate side
chain is then processed in the endoplasmic reticulum
and Golgi network to produce a mature glycoprotein
that is exported through the secretory machinery to the
plasma membrane.
Tunicamycin is a specific inhibitor of N-linked glyco-
sylation that blocks the first step of glycoprotein synth-
esis, thus inhibiting the synthesis of all N-linked
glycoproteins. Interestingly, tunicamycin was shown to
impair the function of several RTKs such as EGFR,
ErbB2, ErbB3, and IGF-IR [12].
We hypothesized that, as demonstrated for other
RTKs [12], ALK function may depend on N-linked gly-
cosylation and we investigated the effects of tunicamycin
on NB cell lines characterized by different ALK altera-
tions. Our results showed that inhibition of N-linked
glycosylation impairs ALK phosphorylation and disrupts
downstream pro-survival signaling, as well as cell viabi-
lity, in NB lines in which ALK is mutated or amplified.
Methods
Cell culture
The following ALK-positive NB cell lines were
employed: SH-SY5Y and KELLY (F1174L ALK muta-
tion), UKF-NB3 (R1275Q ALK mutation) and NB1
(ALK amplified). As a control, we included LA1-5S and
NB5 NB cell lines that are both ALK-negative, and the
ALCL derived cell line SU-DHL1, which harbors the
fusion protein NPM-ALK. Human NB cell line SH-
SY5Y was purchased from the Biological Bank and Cell
Factory core facility (National Cancer Research Institute,
Genoa, Italy) and the LA1-5S cell line was purchased
from the European Collection of Cell Cultures
(ECACC). UKF-NB3, NB1, NB5, KELLY and SU-DHL1
cell lines were kindly provided by the Pediatric Oncol-
ogy Unit (Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy). All cell lines employed in this
study have been rechecked for ALK mutations, altera-
tions and expression levels of the protein. LA1-5S were
grown in MEM/Ham’s F12 1:1 supplemented with non-
essential amino acids and 10% inactivated fetal bovine
(Lonza, Basel, Switzerland). All other cell lines were
grown in RPMI 1,640 supplemented with 10% inacti-
vated fetal bovine serum (Lonza). Tunicamycin was pur-
chased from Sigma-Aldrich (St. Louis, MO).
Western blot analysis
A standard immunoblotting protocol was used to assay
protein expression in cell lysates. Cells were washed
twice with ice-cold PBS and lysed with 100-200 μl of
lysis buffer (Invitrogen, Carlsbad, CA), supplemented
with protease and phosphatase inhibitor cocktails and
PMSF (phenylmethylsulfonyl fluoride) (Sigma-Aldrich).
Lysates were vortexed and incubated on ice for 10 min
twice and then cleared by spinning at 20,000 × g for 10
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min at 4°C. Proteins were separated by 7.5%-10% SDS-
PAGE gels and immunoblotted according to standard
Western blotting procedures using primary antibodies
for ALK, AKT, ERK1/2, STAT3 and related phospho-
proteins (Cell Signaling, Danvers, MA), and either a-
tubulin (Cell Signaling) or GAPDH (Abcam, Cambridge,
UK) as a control for loading of equal amounts of cell
lysates. Goat anti-rabbit and goat anti-mouse IgG HRP
conjugated secondary antibodies were from Jackson
Immunoresearch Inc (Suffolk, UK) and Santa Cruz Bio-
technologies Inc (Santa Cruz, CA), respectively. Blots
were developed with Amersham’s ECL (GE Healthcare,
Waukesha, WI).
Quantification of the western blot bands was per-
formed by ImageJ [13].
MTT assay
Six replicates of SH-SY5Y, KELLY, UKF-NB3, NB1 and
SU-DHL1 (5,000 cells/well) and of LA1-5S (2,500 cells/
well) were plated in 96-well plates with 100 μl RPMI or
MEM + Ham’s F12 medium additioned with 10% fetal
bovine serum. After 24 h cells were treated with
decreasing concentrations of tunicamycin (500 nM -
200 nM - 100 nM - 50 nM - 25 nM), whereas no treat-
ment was done as positive proliferation control. At 48 h,
25 μl of 2 mg/ml MTT (Sigma-Aldrich) was added and
plates incubated for 4 h at 37°C and centrifuged 10 min
at 1,500 rpm. Finally, 150 μl of DMSO were added to
each well and absorbance was read at 560 nm.
FACS analysis
Ethanol fixed cells were incubated with 5 μl annexin-V
FITC conjugate (Invitrogen) for 10 min at room tem-
perature in the dark. Thereafter, cells were centrifuged,
resuspended in 190 μl binding buffer and additioned
with 10 μl propidium iodide (PI) (Sigma-Aldrich). Cells
were analyzed immediately for Annexin-V-FITC and PI
binding, using a FACS (fluorescence activated cell sort-
ing) flow cytometer (CyAn™ Dako). Dot plots and his-
tograms were analyzed by the Dako CyAn - Summit 4.3
software. Annexin-V and PI positive cells were consid-
ered apoptotic. Annexin-V and PI negative cells were
considered viable.
xCELLigence real-time cell analysis
SH-SY5Y, KELLY, NB1, LA1-5S (5,000 cells/well), and
UKF-NB3 (40,000 cells/well) cells were seeded in E-
Plates 16 (Roche, Basel, CH) in appropriate culture
media to a final volume of 200 μl and maintained in a
CO2 incubator at 37°C and 5% CO2 saturation. Dynamic
cell proliferation was monitored in real-time from the
time of plating until the end of the experiment. Elec-
trode impedance at the bottom of each well was
displayed as cell index, which is a direct measure of cell
adhesion and it is a measure that indicates a change in
cell behavior due to an increase or decrease in cell num-
ber, cell adhesion or cell morphology. Adherent NB cell
lines were firstly tested to determine the optimal num-
ber of cells to be plated, and cells were allowed to reach
a cell index of at least 0.5-1 before treatment. Exponen-
tially growing cells were treated in duplicate with
decreasing concentrations of tunicamycin (500 nM, 250
nM and 125 nM). No treatment was used as positive
proliferation control. Cell index values were acquired in
real-time for at least 48 h after treatment. Cell index
curves were calculated for every tunicamycin treatment
and plotted on a graph by Excel.
Results
Inhibition of N-linked glycosylation impairs ALK
phosphorylation and downstream signaling
To investigate the effect that inhibition of N-linked gly-
cosylation could have on ALK phosphorylation and
downstream signaling we treated cells with 500 nM
tunicamycin, a concentration previously employed in
other cell lines of different origin [12], in time course
experiments.
Western blot analysis of protein levels showed the
accumulation of a hypoglycosylated ALK band (180
kDa) and a concomitant decreased of the amount of
mature full size receptor (220 kDa) (Figure 1). Interest-
ingly, after 12 h of treatment, we also observed a
marked decrease of ALK phosphorylation in each of the
NB cell lines harboring ALK mutation or amplification,
and the unphosphorylated status of ALK was still pre-
sent at 48 h (Figure 1). On the contrary, tunicamycin
treatment performed on the ALCL derived cell line SU-
DHL1 did not result in any reduction of the phosphory-
lation levels of NPM-ALK, which lacks N-linked glyco-
sylation consensus sites.
Next, we investigated expression and phosphorylation
levels of proteins involved in ALK signaling (i.e. AKT,
ERK1/2 and STAT3). Tunicamycin treatment did not
affect AKT, ERK1/2 and STAT3 expression (Figure 1),
whereas their phosphorylation levels decreased consider-
ably within 48 h. Noteworthy, we detected an evident
rephosphorylation of STAT3 in SH-SY5Y cells after 48
h of tunicamycin treatment (Figure 1). As tunicamycin
impairs N-linked glycosylation of all newly synthesized
glycoproteins, we also treated LA1-5S, NB5 and SU-
DHL1 cell lines, which do not rely on native ALK as an
oncogenic driver. Intriguingly, tunicamycin did not
affect phosphorylation levels of ALK downstream effec-
tors in these control cell lines, apart from a temporary
reduction of phospho-ERK1/2 levels in LA1-5S cells
(Figure 1).
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Figure 1 Effects of tunicamycin on ALK expression and phosphorylation and on downstream signaling proteins. Cells were exposed to
500 nM tunicamycin and treated in time course experiments. Expression levels of ALK and phosphorylation of ALK (Tyr1604), AKT (Ser473), ERK1/
2 (Thr202/Tyr204), STAT3 (Tyr705) and NPM-ALK (Tyr664) were detected in total cell lysates by Western blot, using corresponding antibodies. a-
tubulin was used as sample loading control. Quantification of western blot bands was performed by using ImageJ software [13]. Quantification
values for each band were firstly normalized to corresponding values of a-tubulin. Then, normalized values for each time were compared to the
corresponding band of the untreated sample (0 hours). Finally the ratio between the phosphorylated form of the proteins and its
unphosphorylated counterpart for each experimental time was calculated and reported with standard deviations.
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Figure 2 Effects of tunicamycin on cell viability. (A) Cell lines were exposed to varying concentrations of tunicamycin for 48 h and cell
survival fractions were measured by MTT assay. (B) Cell lines were exposed to decreasing concentrations of tunicamycin and cell viability
monitored by the xCELLigence™ instrument. The cell index achieved by this technology is a measurement derived from electrical impedance of
cells interacting with microelectrodes on the bottom of a 16-well plate. Cell growth was assessed in real-time for at least 48 h after tunicamycin
administration to cell medium. Arrows indicate time of treatment; CTRL: untreated control. (C) Cells were exposed to 500 nM tunicamycin for 24
and 48 h and analyzed by FACS. The upper plot shows the relative percentage of viable cells, which were double negative for both Annexin-V
and PI. The lower plot shows Annexin-V and PI positive cells, which were considered apoptotic.
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Inhibition of N-linked glycosylation affects cell viability of
ALK-driven NB cell lines
To evaluate the effect of inhibition of N-linked glycosy-
lation on cell survival, cells were cultured for 48 h with
increasing concentrations of tunicamycin, ranging from
25 nM to 500 nM, and cell viability was tested by MTT
assay (Figure 2A). Cell survival fractions were evaluated
in comparison to control cell survival. We observed a
profound inhibition of cell growth in both UKF-NB3
and NB1 cells that showed an IC50 of about 20 nM,
whereas SH-SY5Y and KELLY cells were more resistant,
showing an IC50 of 283 nM and 325 nM, respectively
(Figure 2A). On the other hand, both ALK-negative
LA1-5S cells and NPM-ALK-positive SU-DHL1 cells
were definitely resistant to tunicamycin, showing an
IC50 > 500 nM (Figure 2A).
Cell viability was also analyzed by xCELLigence™
instrument (Roche), which monitors cell adhesion in
real-time (Figure 2B). As a result, cell index of each NB
cell lines harboring ALK mutation or amplification was
extensively impaired, whereas cell index of LA1-5S cells
resulted minimally affected (Figure 2B). Noteworthy, in
contrast to MTT results, we observed a marked decrease
of cell growth also for SH-SY5Y and KELLY cells. In
fact, as for the other ALK-positive cell lines, also SH-
SY5Y and KELLY looked suffering at observation and
most of the cells were detached from the bottom of the
flask after 48 h treatment with 500 nM tunicamycin
(Figure 3).
Finally, cell lines were analyzed by flow cytometry
after double staining with annexin-V and PI. After 48 h
of treatment with 500 nM tunicamycin, SH-SY5Y,
KELLY, UKF-NB3, and NB1 cells showed a cell viability
reduction of 27%, 48%, 42%, and 71%, respectively,
whereas no significant variation was observed in both
LA1-5S and SU-DHL1 cells (Figure 2C). Moreover,
about 6% of KELLY, 13% of UKF-NB3 and 31% of NB1
cells displayed double staining to both annexin-V and
PI, and were considered apoptotic (Figure 2C).
Since both NB1 and UKF-NB3 showed an IC50 greatly
lower than the tunicamycin concentration used in the
first set of experiments, we employed 50 nM tunicamy-
cin in ALK-positive NB cell lines. As a result, we
observed similar effects on ALK and its effectors in NB1
and UKF-NB3 (Figure 4) but not in SH-SY5Y and
KELLY cells, which in fact were more resistant as
detected by MTT assay.
Activation of apoptotic pathways in tunicamycin treated
cells
To investigate the involvement of apoptotic pathways
after inhibition of N-linked glycosylation we analyzed
the following apoptotic proteins: caspase-3, caspase-8,
caspase-9, caspase-12 and the Poly-ADP-ribose-
polymerase (PARP). Cells were exposed to 500 nM tuni-
camycin for 48 h. We did not detect cleavage fragments
in any of the analyzed caspases. On the contrary, we
observed cleavage fragments of PARP in all ALK-posi-
tive NB cell lines but not in control cell lines (Figure
5A). Cleavage fragments of PARP were still present after
treatment of SH-SY5Y and NB1 cells with both 20 μM
of the pan-caspase inhibitor BOC-D-fmk (Calbiochem,
Gibbstown, NJ) and 500 nM of tunicamycin, indicating
a caspase independent activation of PARP (Figure 5B).
Discussion
In the present study, we addressed the question of
whether ALK function may depend on N-linked glycosy-
lation. Inhibition of ALK activity in NB cell lines has
already been approached by using specific small mole-
cule ALK inhibitors, such as PF-2341066 [3], NVP-
TAE684 [4] and CEP14083/CEP14513 [7], and more
recently by RNA interference molecules [14]. Particu-
larly, NB cells harboring either R1275Q mutation or
ALK amplification showed sensitivity to PF-02341066
and these results were also confirmed in xenografts
(Wood AC et al., ASCO Annual Meeting, 2009). How-
ever, NB cell lines with both F1174L ALK mutations
and wild type ALK were more resistant. Furthermore,
two secondary mutations in the kinase domain of the
fusion protein EML4-ALK were discovered in non-
small-cell lung cancer in tumor cells isolated from a
patient during the relapse phase of treatment with the
ALK inhibitor PF-02341066 [15]. Each mutation devel-
oped independently in subclones of the tumor and con-
ferred marked resistance to two different ALK
Figure 3 Photomicrographs of ALK-positive NB cell lines. ALK-
positive NB cell lines were treated with tunicamycin at the
indicated concentrations for 48 h. At a tunicamycin concentration of
500 nM all cell lines looked suffering and most of the cells were
detached.
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inhibitors, PF-02341066 and a 2,4-pyrimidinediamine
derivative (PDD) [15]. Although small molecule inhibi-
tors are a class of anticancer compounds that have
shown promising clinical activity, resistance phenomena
may occur, in part due to either primary and secondary
mutations or to the plasticity of regulation of down-
stream signaling pathways. Hence, great efforts are now
aimed at finding efficient ALK inhibitors, at least for the
more frequent ALK alterations.
In 2008, Contessa and colleagues reported that inhibi-
tion of N-linked glycosylation reduced RTK (i.e. EGFR,
ErbB2, ErbB3 and IGF-IR) signaling through AKT and
radiosensitized tumor cells in glioma and pancreatic
adenocarcinoma cell lines. In comparison, experiments
Figure 4 Effects of tunicamycin 50 nM on NB1 and UKF-NB3 cells. In both NB cell lines that showed a lower IC50 by MTT assay (NB1 and
UKF-NB3) we observed similar effects to those detected by using 500 nM tunicamycin. Quantification of western blot bands was performed by
using ImageJ software [13] as described in Figure 1.
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carried out in nontransformed fibroblastic cells showed
neither a reduction in RTK dependent signaling nor an
enhancement in radiosensitivity [12]. Afterwards, they
also provided evidences that disruption of N-linked gly-
cosylation could reduce RTK signaling in vivo and
increase radiosensitivity of gliomas, suggesting that tar-
geting N-linked glycosylation may combine favorably
with other classes of EGFR inhibitors to reduce both
oncogenic signaling and the mechanisms of therapeutic
resistance [16]. Moreover, tunicamycin was showed to
enhance the susceptibility of lung cancer cells and sensi-
tize resistant cell lines to Erlotinib [17].
Similarly, our results indicated that N-linked glycosy-
lation has a pivotal role also in ALK activation, as
described for EGFR and other RTKs [12]. Tunicamycin
has broad, non-specific effects and acts on all N-linked
glycoproteins. Nevertheless, we specifically investigated
the effects of tunicamycin on NB cell lines that are
dependent on ALK for survival. Here, we showed that
inhibition of N-linked glycosylation led to reduced or
undetectable phosphorylation of ALK. Moreover, we
also observed that pro-survival ALK effectors are
inactivated only in NB cell lines addicted to native ALK
receptor as an oncogenic driver. On the contrary, ALK-
negative NB cell lines did not show evident impairment
of signaling molecules such as AKT, ERK1/2 and
STAT3. Noteworthy, although tunicamycin has broad
effects, we did not observe any variation in the phos-
phorylation levels of ALK effectors in SU-DHL1 cells,
which depend on the unglycosylated cytoplasmatic pro-
tein NPM-ALK. The reactivation of STAT3 observed in
SH-SY5Y cells may be explained by considering a possi-
ble redundancy of cellular signaling networks. Indeed,
multiple RTKs may be coactivated in tumors and redun-
dant inputs drive and maintain downstream signaling
[18,19], although other possibilities should not be ruled
out.
Inhibition of N-linked glycosylation also impaired cell
proliferation only of ALK-positive NB cells. Particularly,
UKF-NB3 and NB1 cells showed high sensitivity to tuni-
camycin by MTT assay, whereas SH-SY5Y and KELLY
cells were less sensitive. However, cell viability assays
carried out by flow cytometry and real-time monitoring
of cell adhesion showed a marked cell growth reduction
Figure 5 Activation of the Poly-ADP-ribose-polymerase (PARP) protein. Cells were treated for 48 h with: (A) 500 nM tunicamycin only; (B)
500 nM tunicamycin and 20 μM of the pan-caspase inhibitor BOC-D-fmk. GAPDH was used as sample loading control. Quantification of western
blot bands was performed by using ImageJ software [13] as described in Figure 1, except the ratio was calculated between the cleaved and the
uncleaved form of PARP.
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for all ALK-positive NB cell lines, including SH-SY5Y
and KELLY. Finally, the cleavage of the Poly-ADP-
ribose-polymerase (PARP) was observed only in ALK-
positive NB cell lines, suggesting that apoptotic path-
ways may be involved in cell death.
Conclusions
In this study we showed that the inhibition of N-linked
glycosylation has the capability to affect ALK phosphor-
ylation and disrupt pro-survival signaling associated to
ALK, indicating that inhibition of this post-translational
modification may be a promising therapeutic approach
for ALK-depending NB patients. Moreover, the contri-
butions of coexpressed growth factor receptors to devel-
oping resistance to therapeutic RTK inhibitors have
been shown, confirming that inhibition of multiple
RTKs may be of therapeutic benefit. Thus, as tunicamy-
cin acts on all N-linked glycoproteins it is plausible to
suppose that, differently from specific small molecule
inhibitors, disruption of N-linked glycosylation should
reduce a reliance on networks of RTKs that may overlap
in effects with ALK.
Since tunicamycin is not a likely candidate for clinical
use our results are to be taken as a proof-of-concept
and other approaches to alter N-linked glycosylation
need to be explored. Future studies will assess whether
the efficacy in inhibiting ALK activity might be
enhanced by the combination of ALK specific small
molecule and N-linked glycosylation inhibitors.
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